— Know what they know.
Not Investment Advice

GTHX NASDAQ

G1 Therapeutics, Inc.
1W: +0.3% 1M: +0.8% 3M: +179.3% 1Y: +379.9% 3Y: -48.7% 5Y: -80.3%
$7.16
Last traded 2024-09-18 — delisted
NASDAQ · Healthcare · Biotechnology · $377.7M mcap · 39M float · 5.56% daily turnover

Balance Sheet Trends

Total Assets
$122M -35.3% ▼
5Y CAGR: -20.0%
Total Liabilities
$86M -27.7% ▼
5Y CAGR: +47.2%
Shareholders Equity
$35M -48.5% ▼
Cash & Investments
$82M -43.3% ▼
5Y CAGR: -26.0%
Total Debt
$57M -31.7% ▼
Net Debt
$25M +329.9% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$269M$207M$221M$95M$32M
Short-Term Investments$0$0$0$50M$50M
Cash & ST Investments$269M$207M$221M$145M$82M
Net Receivables$0$237K$6M$11M$13M
Inventory$0$0$3M$16M$12M
Other Current Assets$63K$63K$63K$7M$8M
Total Current Assets$271M$216M$244M$180M$115M
Property, Plant & Equip.$13M$11M$9M$8M$6M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$437K$437K$312K$250K$187K
Other Non-Current Assets$0$1M$1M$264K$21K
Total Non-Current Assets$14M$12M$11M$8M$7M
Total Assets$285M$229M$254M$188M$122M
— Liabilities —
Accounts Payable$4M$4M$3M$7M$4M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$237K$31K$7K$620K
Other Current Liabilities$3M$7M$5M$7M$8M
Total Current Liabilities$20M$23M$28M$36M$30M
Long-Term Debt$10M$20M$75M$77M$52M
Other Non-Current Liab.-$10M$0$0$0$41K
Total Non-Current Liabilities$10M$28M$83M$84M$56M
Total Liabilities$29M$51M$111M$119M$86M
— Equity —
Common Stock$4K$4K$4K$5K$5K
Retained Earnings-$337M-$436M-$584M-$732M-$780M
Accumulated OCI$0$0-$0-$0-$0
Total Stockholders Equity-$337M-$436M-$584M$69M$35M
Total Liabilities & Equity-$308M-$385M-$474M$188M$122M
— Key Metrics —
Total Debt$10M$28M$83M$84M$57M
Net Debt-$259M-$180M-$138M-$11M$25M
Total Investments$437K$437K$312K$50M$50M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms